8 results on '"Frimodt-Moller B"'
Search Results
2. 1294P RELAY, erlotinib plus ramucirumab or placebo in untreated EGFR-mutated metastatic NSCLC: Outcomes by EGFR mutation type
3. RELAY : étude de phase 3 internationale en double aveugle et randomisée comparant l’erlotinib (ERL) associé au ramucirumab (RAM) ou à un placebo (PL) comme traitement de première ligne chez des patients atteints d’un cancer bronchique non à petites cellules (CBNPC) métastatique avec une mutation du récepteur du facteur de croissance épidermique (EGFRm)
4. Patient-focused outcomes in RELAY, a phase III trial of ramucirumab plus erlotinib (RamErl) versus placebo plus ERL (PboErl) in untreated EGFR-mutated metastatic NSCLC (EGFR+ mNSCLC)
5. P1.18-01 RELAY EU/US Subset: Ramucirumab Plus Erlotinib Improves Progression-Free Survival in First-Line EGFR Mutation-Positive NSCLC
6. 135O A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer
7. Phase 1b expansion cohort study to evaluate the safety and efficacy of necitumumab and abemaciclib combination therapy in patients with stage IV non-small cell lung cancer (NSCLC)
8. P-458 Palliative chemotherapy of non-small cell lung cancer (NSCLC): Analysis of German baseline data from the ACTION observational study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.